| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 06/28/2001 | CA2395466A1 Interventions to mimic the effects of calorie restriction |
| 06/28/2001 | CA2395435A1 Cosmid dna constructs and methods of making and using the same |
| 06/28/2001 | CA2395411A1 Use of dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants |
| 06/28/2001 | CA2395406A1 Method for treating inflammation |
| 06/28/2001 | CA2395202A1 Hydrazone and oxime derivatives of pyrrolidine as amp-specific phosphodiesterase inhibitors |
| 06/28/2001 | CA2395113A1 Pyrazole cyclic amp-specific pde inhibitors |
| 06/28/2001 | CA2395108A1 Method of treating gastrointestinal tract disease with purinergic receptor agonists |
| 06/28/2001 | CA2395102A1 Human kinases |
| 06/28/2001 | CA2395007A1 Transporters and ion channels |
| 06/28/2001 | CA2394901A1 Chitosan biopolymer for the topical delivery of active agents |
| 06/28/2001 | CA2394877A1 Compounds and use thereof to modify transport across cell membranes |
| 06/28/2001 | CA2394834A1 Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b) |
| 06/28/2001 | CA2394789A1 Proteases |
| 06/28/2001 | CA2394743A1 Inhibition of .beta.arrestin mediated effects prolongs and potentiates opioid receptor-mediated analgesia |
| 06/28/2001 | CA2394568A1 Tissue sensitizing compounds for females with methods and apparatus for the delivery of these compounds |
| 06/28/2001 | CA2394524A1 N,n'-bis(2-hydroxybenzyl)ethylenediamine-n,n'-diacetic acid in iron chelating therapy |
| 06/28/2001 | CA2394330A1 Pharmaceutical composition comprising a physiologically acceptable vanadium compound, salt or complex and at least a component selected from a na+/h+ exchanger inhibitors, cyclo-oxygenase inhibitors and caspase inhibitors |
| 06/28/2001 | CA2394222A1 Sustained-release formulation of a cyclooxygenase-2 inhibitor |
| 06/28/2001 | CA2394049A1 Vesicle trafficking proteins |
| 06/28/2001 | CA2394015A1 Tweak receptor |
| 06/28/2001 | CA2393855A1 Homologues of human heparanase and splice variants thereof |
| 06/28/2001 | CA2393767A1 Molecules derived from mechanism based drug design |
| 06/28/2001 | CA2393724A1 Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use |
| 06/28/2001 | CA2393646A1 Survivin promotion of angiogenesis |
| 06/28/2001 | CA2393367A1 Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b) |
| 06/28/2001 | CA2393363A1 Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b) |
| 06/28/2001 | CA2393359A1 Aromatic phosphonates as protein tyrosine phosphatase 1b (ptp-1b) inhibitors |
| 06/28/2001 | CA2392554A1 Inhibitors of thrombin induced platelet aggregation |
| 06/28/2001 | CA2384326A1 Compositions and methods for l-nucleosides, l-nucleotides, and their analogs |
| 06/27/2001 | EP1110970A1 Anti-Procalcitonin antibody, their production and use |
| 06/27/2001 | EP1110949A1 EP4 receptor selective agonists in the treatment of osteoporosis |
| 06/27/2001 | EP1110556A1 Preventives/remedies for multiple organ failure |
| 06/27/2001 | EP1110552A1 Use of a compound with affinity for the mitochondrial benzodiazepine receptor in cancer therapy |
| 06/27/2001 | EP1110544A2 Use of a film coating as taste masking coating for oral dosage forms |
| 06/27/2001 | EP1110543A2 Extended release oral dosage composition |
| 06/27/2001 | EP1109935A2 Two-colour differential display, used as a method for detecting regulated genes |
| 06/27/2001 | EP1109908A2 Leptin induced genes |
| 06/27/2001 | EP1109907A1 Human cell junction pdz protein |
| 06/27/2001 | EP1109906A1 Methods and compositions for modulating the interaction between the apj receptor and the hiv virus |
| 06/27/2001 | EP1109905A1 Genes encoding for the human and murine death inducer-obliterator-1 |
| 06/27/2001 | EP1109903A2 Human rna-associated proteins |
| 06/27/2001 | EP1109901A2 GABA B RECEPTOR SUBTYPES GABA B-R1c AND GABA B-R2 AND HETERODIMERS THEREOF |
| 06/27/2001 | EP1109900A1 Angiocidin: a cys-ser-val-thr-cys-gly specific tumor cell adhesion receptor |
| 06/27/2001 | EP1109833A2 Compositions and methods for the treatment of tumors |
| 06/27/2001 | EP1109830A1 Mc4-r as target for the identification of compounds used to treat drug addiction |
| 06/27/2001 | EP1109829A1 Human latent transforming growth factor beta binding protein 3 |
| 06/27/2001 | EP1109828A1 Peptide fragments of cholera toxin b or enterotoxin b as vaccine adjuvants |
| 06/27/2001 | EP1109822A1 Factor 8 homologue nucleic acids, polypeptides, methods, uses |
| 06/27/2001 | EP1109817A1 Phosphohalohydrins, method for making same and uses |
| 06/27/2001 | EP1109805A1 Inhibitors of bacterial nad synthetase |
| 06/27/2001 | EP1109580A1 Methods for treating or preventing viral infections and associated diseases |
| 06/27/2001 | EP1109578A1 Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis |
| 06/27/2001 | EP1109572A2 Neuroprotection |
| 06/27/2001 | EP1109571A2 Methods of treating hypertension and compositions for use therein |
| 06/27/2001 | EP1109570A2 Method of modulating memory effector t-cells and compositions |
| 06/27/2001 | EP1109569A2 Regulation of lung tissue by hedgehog-like polypeptides, and formulations and uses related thereto |
| 06/27/2001 | EP1109567A1 Drug screening and diagnosis based on paracrine tubular renin-angiotensin system |
| 06/27/2001 | EP1109566A1 Gcp |
| 06/27/2001 | EP1109565A1 Gabab1aa receptor |
| 06/27/2001 | EP1109561A1 Promoters of neural regeneration |
| 06/27/2001 | EP1109559A2 Inhibition of pathogenic processes related to tissue trauma |
| 06/27/2001 | EP1109556A2 New pharmaceutical uses for nos inhibitors |
| 06/27/2001 | EP1109554A2 Pipecolic acid derivatives for vision and memory disorders |
| 06/27/2001 | EP1109547A1 New use of taxoid derivatives |
| 06/27/2001 | EP1109546A1 Ophthalmic compositions for treating ocular hypertension |
| 06/27/2001 | EP1109543A1 Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
| 06/27/2001 | EP1109542A1 Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use |
| 06/27/2001 | EP1109539A1 Nanogel networks and biological agent composition thereof |
| 06/27/2001 | EP1109534A1 Quick release pharmaceutical compositions of drug substances |
| 06/27/2001 | EP1109506A1 Improved method for targeted topical treatment of disease |
| 06/27/2001 | EP1109454A2 Neisseria meningitidis polypeptide, nucleic acid sequence and uses thereof |
| 06/27/2001 | EP0800394A4 Prevention of adverse behaviour, diarrhoea, skin disorders and infections of the hind gut associated with acidic conditions in humans and animals |
| 06/27/2001 | EP0767669B1 New pharmaceutical preparation for pain management |
| 06/27/2001 | EP0727979B1 Novel composition |
| 06/27/2001 | CN1301298A Methods for prevention and treatment of cancer |
| 06/27/2001 | CN1301181A Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery |
| 06/27/2001 | CN1301167A Treatment of organophosphate poisoning |
| 06/27/2001 | CN1301165A Medicament for preventing and/or treating a mammary carcinoma, containing a steroidal aromatase inhibitor |
| 06/27/2001 | CN1301162A Method for combating obesity |
| 06/27/2001 | CN1301158A Compositions for the treatment of HIV and other viral infections |
| 06/27/2001 | CN1301156A Treatment of T-Helper cell tyre 2 mediated immune diseases with retinoid antagonists |
| 06/27/2001 | CN1301147A Pharmaceutical compositions capable of being gelled |
| 06/27/2001 | CN1300628A Colloidal perfusate containing cells for peritoneal dialysis |
| 06/27/2001 | CN1300590A Use of coating as taste masking agent for oral preparation |
| 06/27/2001 | CN1067550C Calcium receptor active molecules |
| 06/26/2001 | US6252044 Riboflavin synthase polypeptide; for the controlled biosynthesis of riboflavin; for screening bactericides; for prevention of infection |
| 06/26/2001 | US6252043 Fusion protein for the treatment of inflammation; for the detection and prevention of leukocyte adhesion to endothelial cells |
| 06/26/2001 | US6251945 Pharmaceutical mixture comprising a combination of a profen and other active compounds |
| 06/26/2001 | US6251942 Compositions and methods for alleviating impaired mental function, memory loss and reducing recovery time in anaesthetized mammals |
| 06/26/2001 | US6251935 Administration of a racemic alpha-lipoic acid, enantiomers and pharmaceutically acceptable salts, amides, esters or thioester, in reduced or oxidized form as antimigraine agent |
| 06/26/2001 | US6251927 Treating sickle cell anemia using protected forms of organic aldehydes |
| 06/26/2001 | US6251924 Pharmaceutical composition |
| 06/26/2001 | US6251902 Dipeptide derivatives as growth hormone secretagogues |
| 06/26/2001 | US6251889 Orally administering composition comprising chromic tripicolinate in combination with picolinic acid to individual to facilitate absorption of one or more essential metals |
| 06/26/2001 | US6251883 Methods for preparation and use of 1α,24(S)-dihydroxy vitamin D2 |
| 06/26/2001 | US6251874 If hiv viral load in blood of patient is above specified amount, administering hydroxyurea, dideoxyinosine and indinavir until viral load is reduced; if viral load is below that specified, administering hydroxyurea and dideoxyinosine |
| 06/26/2001 | US6251870 Pharmaceutical composition for inhibiting growth of cancers |
| 06/26/2001 | US6251867 Antiangiogenic peptides and methods for inhibiting angiogenesis |
| 06/26/2001 | US6251866 A water soluble, biocompatible polymer, a chemical agent covalently, releasably coupled to the polymer and an interleukin-2-receptor binding peptide of given sequence covalently coupled to the polymer |
| 06/26/2001 | US6251865 Insulin-like growth factor agonist molecules |